Neurology

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a family of enzymes it discovered called nitrases. It is working on treatments that aim these enzymes to decrease or even prevent, the progression of various diseases, commencing with Parkinson's. Sofinnova and AbbVie had led the USD 38 million series A, with Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments also pitching in. The pr...